BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-752. [PMID: 32413340 DOI: 10.1016/s2468-1253(20)30077-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 38] [Article Influence: 42.5] [Reference Citation Analysis]
Number Citing Articles
1 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
2 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
3 Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism 2021;126:154911. [PMID: 34648769 DOI: 10.1016/j.metabol.2021.154911] [Reference Citation Analysis]
4 Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne) 2021;8:693507. [PMID: 34277667 DOI: 10.3389/fmed.2021.693507] [Reference Citation Analysis]
5 Velázquez AM, Roglans N, Bentanachs R, Gené M, Sala-Vila A, Lázaro I, Rodríguez-Morató J, Sánchez RM, Laguna JC, Alegret M. Effects of a Low Dose of Caffeine Alone or as Part of a Green Coffee Extract, in a Rat Dietary Model of Lean Non-Alcoholic Fatty Liver Disease without Inflammation. Nutrients 2020;12:E3240. [PMID: 33113993 DOI: 10.3390/nu12113240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Poul SS, Parker KJ. Fat and fibrosis as confounding cofactors in viscoelastic measurements of the liver. Phys Med Biol 2021;66:045024. [PMID: 33348325 DOI: 10.1088/1361-6560/abd593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Chin YH, Tan HQM, Ng CH, Tan DJH, Lin SY, Huang DQ, Khoo CM, Muthiah MD. A Time-Based Meta-Analysis on the Incidence of New Onset Diabetes after Liver Transplantation. J Clin Med 2021;10:1045. [PMID: 33802465 DOI: 10.3390/jcm10051045] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. World J Gastroenterol 2020; 26(42): 6514-6528 [PMID: 33268944 DOI: 10.3748/wjg.v26.i42.6514] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Roeb E. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Visc Med 2021;37:273-80. [PMID: 34540943 DOI: 10.1159/000515445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Patoulias D. Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken? J Clin Transl Hepatol 2021;9:454-5. [PMID: 34447672 DOI: 10.14218/JCTH.2021.00236] [Reference Citation Analysis]
11 Xiao J, Yong JN, Ng CH, Syn N, Lim WH, Tan DJH, Tan EY, Huang D, Wong RC, Chew NWS, Tan EXX, Noureddin M, Siddiqui MS, Muthiah MD. A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver Transpl 2021. [PMID: 34626045 DOI: 10.1002/lt.26331] [Reference Citation Analysis]
12 Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int 2021;15:405-12. [PMID: 33539004 DOI: 10.1007/s12072-021-10147-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M, Zhao Z, Xu Y, Lu J, Chen Y, Wang W, Ning G, Bi Y, Xu M. Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutr Metab (Lond) 2021;18:21. [PMID: 33608033 DOI: 10.1186/s12986-021-00551-6] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther 2021. [PMID: 34866201 DOI: 10.1111/apt.16720] [Reference Citation Analysis]
16 Sheng G, Peng N, Hu C, Zhong L, Zhong M, Zou Y. The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population. Lipids Health Dis 2021;20:50. [PMID: 33993872 DOI: 10.1186/s12944-021-01479-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021;20:139. [PMID: 34657611 DOI: 10.1186/s12944-021-01573-y] [Reference Citation Analysis]
18 Zou Y, Zhong L, Hu C, Zhong M, Peng N, Sheng G. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. Lipids Health Dis 2021;20:28. [PMID: 33766067 DOI: 10.1186/s12944-021-01457-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
21 So WZ, Tan FL, Tan DJH, Ng CH, Yong JN, Syn N, Tang ASP, Wong RC, Lin W, Tan EXX, Huang DQ, Dan YY, Chew NWS, Siddiqui MS, Muthiah MD. A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. Dig Liver Dis 2021:S1590-8658(21)00851-3. [PMID: 34896025 DOI: 10.1016/j.dld.2021.11.011] [Reference Citation Analysis]
22 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Deng J, Zhang Y, Bu L, Shi H, Tang H, Wang S, Wang Q, Dang S, Li M, Han Z, Lu X. The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:744710. [PMID: 34603215 DOI: 10.3389/fendo.2021.744710] [Reference Citation Analysis]
24 Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y, Kumar R, Lin S. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis. Diabetes Metab Syndr Obes 2021;14:3417-25. [PMID: 34349535 DOI: 10.2147/DMSO.S316096] [Reference Citation Analysis]
25 Singh A, Gupta V. SARS-CoV-2 therapeutics: how far do we stand from a remedy? Pharmacol Rep 2021;73:750-68. [PMID: 33389724 DOI: 10.1007/s43440-020-00204-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00747-3. [PMID: 34265444 DOI: 10.1016/j.cgh.2021.07.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01183-6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Reference Citation Analysis]
28 Xiao J, Lim LKE, Ng CH, Tan DJH, Lim WH, Ho CSH, Tan EXX, Sanyal AJ, Muthiah MD. Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:691696. [PMID: 34277666 DOI: 10.3389/fmed.2021.691696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rahman MM, Kibria MG, Begum H, Haque M, Sultana N, Akhter M, Rowshon AHM, Ahmed F, Hasan M. Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. BMJ Open Gastroenterol 2020;7:e000535. [PMID: 33376110 DOI: 10.1136/bmjgast-2020-000535] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Kositamongkol C, Charernboon T, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Charatcharoenwitthaya P, Phisalprapa P. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome. Medicine (Baltimore) 2021;100:e27640. [PMID: 34871234 DOI: 10.1097/MD.0000000000027640] [Reference Citation Analysis]
31 Słomko J, Zalewska M, Niemiro W, Kujawski S, Słupski M, Januszko-Giergielewicz B, Zawadka-Kunikowska M, Newton J, Hodges L, Kubica J, Zalewski P. Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:1659. [PMID: 33924482 DOI: 10.3390/jcm10081659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Poss AM, Summers SA. Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD. Front Endocrinol (Lausanne) 2020;11:505. [PMID: 32849291 DOI: 10.3389/fendo.2020.00505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Jiang W, Liu CH, Wu D, Wang YJ, Tang H. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Biosci Rep 2021;41:BSR20211769. [PMID: 34918746 DOI: 10.1042/BSR20211769] [Reference Citation Analysis]
34 Peng Y, Zeng Q, Wan L, Ma E, Li H, Yang X, Zhang Y, Huang L, Lin H, Feng J, Xu Y, Li J, Liu M, Liu J, Lin C, Sun Z, Cheng G, Zhang X, Liu J, Li D, Wei M, Mo Y, Mu X, Deng X, Zhang D, Dong S, Huang H, Fang Y, Gao Q, Yang X, Wu F, Zhong H, Wei C. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun 2021;12:7004. [PMID: 34853313 DOI: 10.1038/s41467-021-27309-1] [Reference Citation Analysis]
35 Tay PWL, Xiao J, Tan DJH, Ng C, Lye YN, Lim WH, Teo VXY, Heng RRY, Yeow MWX, Lum LHW, Tan EXX, Kew GS, Lee GH, Muthiah MD. An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis. Front Med (Lausanne) 2021;8:693652. [PMID: 34422858 DOI: 10.3389/fmed.2021.693652] [Reference Citation Analysis]
36 Khayyat YM. Determination of “indeterminate score” measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia. World J Hepatol 2021; 13(12): 2150-2160 [DOI: 10.4254/wjh.v13.i12.2150] [Reference Citation Analysis]
37 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Semmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, Stickel F, Niederseer D, Aigner E, Datz C. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. Clin Transl Gastroenterol 2021;12:e00326. [PMID: 33821832 DOI: 10.14309/ctg.0000000000000326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Moustakas II, Katsarou A, Legaki AI, Pyrina I, Ntostoglou K, Papatheodoridi AM, Gercken B, Pateras IS, Gorgoulis VG, Koutsilieris M, Chavakis T, Chatzigeorgiou A. Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity. Int J Mol Sci 2021;22:3446. [PMID: 33810566 DOI: 10.3390/ijms22073446] [Reference Citation Analysis]
40 Bilic-Curcic I, Cigrovski Berkovic M, Virovic-Jukic L, Mrzljak A. Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals . World J Hepatol 2021; 13(1): 80-93 [PMID: 33584988 DOI: 10.4254/wjh.v13.i1.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
42 Hou XD, Yan N, Du YM, Liang H, Zhang ZF, Yuan XL. Consumption of Wild Rice (Zizania latifolia) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model. Int J Mol Sci 2020;21:E5375. [PMID: 32751062 DOI: 10.3390/ijms21155375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Premkumar M, Anand AC. Lean Fatty Liver Disease: Through Thick and Thin. J Clin Exp Hepatol 2021;11:523-7. [PMID: 34511811 DOI: 10.1016/j.jceh.2021.06.011] [Reference Citation Analysis]
44 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Reference Citation Analysis]
45 Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, Kuroki H, Kawata H, Abe H, Nouno R, Kawaguchi K, George J, Mitsuyama K, Torimura T. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. Int J Mol Sci 2021;22:5462. [PMID: 34067258 DOI: 10.3390/ijms22115462] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
47 Toh JZK, Pan XH, Tay PWL, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Tan EXX, Dan YY, Loh PH, Foo R, Chew NWS, Sanyal AJ, Muthiah MD, Siddiqui MS. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01035-1. [PMID: 34560278 DOI: 10.1016/j.cgh.2021.09.021] [Reference Citation Analysis]
48 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Reference Citation Analysis]
49 Izzo C, Annunziata M, Melara G, Sciorio R, Dallio M, Masarone M, Federico A, Persico M. The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. Nutrients 2021;13:933. [PMID: 33805795 DOI: 10.3390/nu13030933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Liu F, Ye Q, Liang J, Cao YY, Shi LL, Zhao X, Xiang HL. Nutritional status and energy metabolism in elderly patients with nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(9): 467-473 [DOI: 10.11569/wcjd.v29.i9.467] [Reference Citation Analysis]
51 Yang H, Arif M, Yuan M, Li X, Shong K, Türkez H, Nielsen J, Uhlén M, Borén J, Zhang C, Mardinoglu A. A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease. iScience 2021;24:103222. [PMID: 34712920 DOI: 10.1016/j.isci.2021.103222] [Reference Citation Analysis]
52 Liu J, Wang G, Wu Y, Guan Y, Luo Z, Zhao G, Jiang Y. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults. Nutrients 2021;13:4063. [PMID: 34836318 DOI: 10.3390/nu13114063] [Reference Citation Analysis]
53 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
54 Liu F. Ultrasound-based techniques for noninvasive diagnosis of liver steatosis in nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(10): 543-549 [DOI: 10.11569/wcjd.v29.i10.543] [Reference Citation Analysis]
55 Li HY, Gan RY, Shang A, Mao QQ, Sun QC, Wu DT, Geng F, He XQ, Li HB. Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application. Oxid Med Cell Longev 2021;2021:6621644. [PMID: 33728021 DOI: 10.1155/2021/6621644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Manka PP, Kaya E, Canbay A, Syn WK. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3676-88. [PMID: 34410573 DOI: 10.1007/s10620-021-07206-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Wiese MD, Meakin AS, Varcoe TJ, Darby JRT, Sarr O, Kiser P, Bradshaw EL, Regnault TRH, Morrison JL. Hepatic cytochrome P450 function is reduced by life-long Western diet consumption in guinea pig independent of birth weight. Life Sci 2021;287:120133. [PMID: 34774623 DOI: 10.1016/j.lfs.2021.120133] [Reference Citation Analysis]
58 Patoulias D, Doumas M. Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"? Clin Mol Hepatol 2020;26:582-3. [PMID: 32971587 DOI: 10.3350/cmh.2020.0264] [Reference Citation Analysis]
59 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Reference Citation Analysis]
60 Huang H, Wang J, Xu L, Miao M, Xu C. Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Int J Endocrinol 2021;2021:6676526. [PMID: 34194492 DOI: 10.1155/2021/6676526] [Reference Citation Analysis]
61 Ali S, Haque N, Azhar Z, Saeinasab M, Sefat F. Regenerative Medicine of Liver: Promises, Advances and Challenges. Biomimetics (Basel) 2021;6:62. [PMID: 34698078 DOI: 10.3390/biomimetics6040062] [Reference Citation Analysis]
62 Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Arvind A, Henson JB, Osganian SA, Nath C, Steinhagen LM, Memel ZN, Donovan A, Balogun O, Chung RT, Simon TG, Corey KE. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021. [PMID: 34558862 DOI: 10.1002/hep4.1818] [Reference Citation Analysis]
64 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
65 Wong J, Goh QY, Tan Z, Lie SA, Tay YC, Ng SY, Soh CR. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore. Can J Anaesth. 2020;67:732-745. [PMID: 32162212 DOI: 10.1007/s12630-020-01620-9] [Cited by in Crossref: 315] [Cited by in F6Publishing: 254] [Article Influence: 157.5] [Reference Citation Analysis]
66 Urata N, Kawanaka M, Nishino K, Ishii K, Tanikawa T, Suehiro M, Sasai T, Haruma K, Kawamoto H, Nakamura J, Manabe N, Kamada T. Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals: A Cross-Sectional Study. Life (Basel) 2020;10:E175. [PMID: 32899741 DOI: 10.3390/life10090175] [Reference Citation Analysis]
67 Kitazawa A, Maeda S, Fukuda Y. Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data. PLoS One 2021;16:e0257352. [PMID: 34543321 DOI: 10.1371/journal.pone.0257352] [Reference Citation Analysis]